Drug Profile


Alternative Names: Q45; WR 006026; WR 6026

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Walter Reed Army Institute of Research
  • Class Antiprotozoals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Babesiosis; Visceral leishmaniasis

Most Recent Events

  • 03 Sep 2005 This compound is still in active development for Visceral leishmaniasis
  • 11 May 2004 No development reported - Preclinical for Babesiosis in USA (unspecified route)
  • 31 Dec 2003 Phase-II clinical trials in Visceral leishmaniasis in India (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top